Alcobra Ltd. to Present at AACAP's 60th Annual Meeting on October 24th

TEL AVIV, Israel, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), today announced that it will be presenting at AACAP's 60th Annual Meeting. The conference is being held at the Walt Disney World Dolphin Hotel in Orlando, FL from October 22nd to the 27th.

Lenard Adler M.D., Professor of Psychiatry and Child and Adolescent Psychiatry at New York University School of Medicine and Chairperson of Alcobra Ltd.'s Clinical Advisory Board, is scheduled to give an oral presentation titled: Treatment of Adult ADHD - Preferential Effects of Metadoxine Extended-Release on Inattentive Subtype ADHD. The presentation will take place on Thursday, October 24th between 8:30 a.m. – 11:30 a.m. Following Dr. Adler's presentation/session, his presentation will be available on Alcobra's website at

About Alcobra Ltd.

Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel.


Representing over 8,500 child and adolescent psychiatrists nationwide, the American Academy of Child and Adolescent Psychiatry (AACAP) is the leading authority on children's mental health. AACAP Members actively research, diagnose and treat psychiatric disorders affecting children, adolescents and their families. For more information please visit

CONTACT: U.S. Investor Contacts: KCSA Strategic Communications Jeffrey Goldberger / Garth Russell +1 212.896.1249 / +1 212.896.1250 / Israel Investor Contact: Investor Relations Ltd. Moran Meir-Beres +011972-3-5167620 Ltd.